A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
What is the purpose of this trial?
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread
- Trial withBristol-Myers Squibb Research and Development
- Start Date10/31/2019
- End Date08/14/2023
- Last Updated11/04/2019
- Study HIC#2000023840